Navigation Links
The International Myeloma Foundation Reports Positive Shift In,Treatment Paradigm For Patients

-Second Closure of Multi-Center Trial in 4 Weeks Reinforces Benefits of Using REVLIMID with Low Dose Steroids in Myeloma-

NORTH HOLLYWOOD, Calif., May 15, 2007 /PRNewswire/ -- The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said that for the second time in four weeks a multi-center myeloma trial using REVLIMID(R) has demonstrated positive findings and therefore has been halted early. As a result medical experts are backing the use of new, less toxic and more tolerable treatments for multiple myeloma, the second most common of the blood cancers in the United States.

    -- In April, the Eastern Cooperative Oncology Group (ECOG) stopped the use

       of high dose dexamethasone, a steroid commonly used when treating

       patients with REVLIMID, (lenalidomide) an oral medication from Celgene.

       Based on the findings, the data safety monitoring committee recommended

       all patients in the study be moved to a regimen of REVLIMID with low-

       dose dexamethasone, which demonstrated improved survival and was better

       tolerated.

    -- Now based on these findings and early analysis of its own data the

       Southwest Oncology Group (SWOG), the largest of the NIH sponsored

       multi-center cooperative group, has brought its trial of high dose

       dexamethasone versus Revlimid plus high dose dexamethasone to an early

       close and also recommended patients be transitioned to a REVLIMID/LDD

       regimen.

    -- Based on these findings, The International Myeloma Foundation's US

       MYELOMA FORUM, a committee of the nation's leading myeloma experts, is

       considering the first large, inter-group trial for newly-diagnosed

       patients using novel agents (either REVLIMID with low-dose

       dexamethasone  or REVLIMD plus other agents such as VELCADE(R) with

       low-dose dexameth
'"/>




Page: 1 2 3

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... District Court for the District of New ... the company,s case against Sandoz, Inc. regarding United Therapeutics, ... Sheridan ruled that U.S. Patent No. 6,765,117 is ... Sandoz from marketing its generic product until the expiration ...
(Date:8/29/2014)... , August 29, 2014 ... Market by Product & Services (Equipment, Reagent, Primer, ... Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, ... MarketsandMarkets, the global Oligonucleotide Synthesis Market is expected ... Million in 2014, growing at a CAGR of ...
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
(Date:9/1/2014)... is a leading review website in the world. It ... announced that GreenGeeks, Arvixe and Hostgator are the best ... http://www.greengeeks.com/cgi-bin/affiliates/clickthru.cgi?id=seohosts ) is one of the best web hosting ... of useful products for sale. On its website, customers ... , As one of the Top 10 Web Hosting ...
(Date:9/1/2014)... may be bad for your waistline. TV viewers ate ... excerpt from a Hollywood action film than those watching ... for helping Americans to gain weight because it encourages ... been on the medium and not the message. TV ... to eat more, including reading, listening to the radio ...
(Date:9/1/2014)... 1, 2014 (HealthDay News) -- You may be able to ... ones, new research suggests. The study included eight overweight ... weight-loss program meant to change how people react to different ... five overweight and obese people who weren,t in the program. ... of the study and again six months later. The scans ...
(Date:9/1/2014)... Albany, New York (PRWEB) September 01, 2014 ... specially-fitted room in a hospital for performing surgical operations. ... such as operating tables, surgical booms, operating room lights, ... rooms. According to a report by Transparency Market Research, ... market is expected to reach USD 4.5 billion by ...
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. 29, 2014 (HealthDay ... American aid workers successfully cured a group of monkeys infected ... The drug, ZMapp, prompted recovery in all 18 monkeys who ... five days after infection. ZMapp even cured monkeys with ... away from death, said study senior author Gary Kobinger, chief ...
Breaking Medicine News(10 mins):Health News:The Best Reseller Hosting Suppliers in August Released by Leading Review SiteTop10BestSEOHosting.com 2Health News:Research letter: Viewers ate more while watching Hollywood action flick on TV 2Health News:Train Your Brain to Choose Fruit Salad Over French Fries 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3
... Two new vitamin D studies using a sophisticated form of ... combined, have revealed new prescriptions for// possibly preventing up to ... the cases of colorectal cancer in the United States. The ... specialists at the Moores Cancer Center at University of California, ...
... older men experience the symptoms of an enlarged prostate multiple ... know is that the disease// known as BPH (benign prostatic ... but at least a pair of disorders, and that one ... — has far more serious implications. ,In a ...
... not sound like such a bad thing. But a condition ... PCOS – can present women with numerous health concerns, ranging ... risk of heart disease and diabetes. ,PCOS affects ... one of the more common hormonal abnormalities women experience during ...
... use for checking body temperature is most lethal and ... ,Mercury is a neurotoxin, meaning it attacks the ... has been linked to birth defects, learning disabilities, walking ... ,In adults, mercury poisoning leads to tremors, headaches, ...
... of launching an oral vaccine for diabetes that would ... to millions in the country// suffering from the debilitating ... Transgene Biotek Ltd is currently doing research and pre-clinical ... Institute of Chemical Technology (IICT), Hyderabad. ,"We ...
... dead pregnant woman on life support had passed the milestone ... outside the womb, giving her family new hope. The family ... was a possible name the couple had discussed before her ... have assumed an important criterion in the use and abuse ...
Cached Medicine News:Health News:Two New Studies Back Vitamin D for Cancer Prevention 2Health News:Two New Studies Back Vitamin D for Cancer Prevention 3Health News:Severe Form of “Enlarged Prostate” Disease Discover 2Health News:Condition That Causes Irregular Periods Can Lead to Fertility Problems 2Health News:Condition That Causes Irregular Periods Can Lead to Fertility Problems 3Health News:Mercury can Kill 2Health News:Mercury can Kill 3Health News:India Developing Oral Vaccine to Fight Diabetes 2Health News:Ultrasound Technology - Boon or a Bane? 2Health News:Ultrasound Technology - Boon or a Bane? 3Health News:Ultrasound Technology - Boon or a Bane? 4
...
Cobb Curettes, reverse angled, 11"....
Malis Needle Holders, bayonet, titanium. Working distance 2 1/2" (63 mm). Straight tip with width 0.6 mm....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Medicine Products: